Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Michael Polansky has a new, skin-focused biotech. Don't call it a drug company.

27 August 2026 · By · Wire by Fusion42

Published

27 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biopharmadive.com →

◆ Verified

Fusion42 · 27 August 2026 · Fusion42 review

Michael Polansky has launched Outer Bio, a biotech focused on skin biology that deliberately avoids the regulatory complexities of traditional drug development by positioning itself outside the drug category while leveraging data valuable for pharmaceutical companies.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a new type of biotech that bypasses traditional drug development hurdles by focusing on skin health without claiming to be a drug company. You can explore partnerships leveraging its data insights while avoiding extensive regulator delays.

◆ Coverage

1 source · 27 Aug 2026

◆ Related on Wire

◆ Topics

Biotechskin-biotechcosmetics-vs-pharmaregulatory-positioningmichael-polanskydata-driven-biotech